Idarubicin

Notable Labs Presents Clinical Platform Validation Data at the 2023 American Association for Cancer Research Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023

FOSTER CITY, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced clinical data regarding its Predictive Precision Medicine Platform (PPMP) at the 2023 American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida from April 14-19, 2023.

Key Points: 
  • FOSTER CITY, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced clinical data regarding its Predictive Precision Medicine Platform (PPMP) at the 2023 American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida from April 14-19, 2023.
  • We are excited about these clinical results as they not only corroborate, but expand upon, those of our three other validation trials.
  • That is, all patients predicted to respond clinically actually did while those patients predicted not to respond, did not.
  • A PPV of 100% indicates, for example, that a clinical trial selectively enrolling predicted clinical responders would result in a 100% response rate.

Jacobson Pharma Announces FY2022 Annual Results

Retrieved on: 
Wednesday, June 29, 2022

HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").

Key Points: 
  • HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2022 ACN Newswire .

Roswell Park Expert to Present on Effectiveness of New Combination for Acute Myeloid Leukemia

Retrieved on: 
Monday, June 6, 2022

CHICAGO, June 6, 2022 /PRNewswire-PRWeb/ -- On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML). Dr. Wang will discuss the findings at the American Society of Clinical Oncology (ASCO) annual meeting 2022, at 11:57 a.m. CDT, in Hall S, room 100a, during the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant oral abstract session (abstract 7007).

Key Points: 
  • CHICAGO, June 6, 2022 /PRNewswire-PRWeb/ -- On Tuesday, June 7, Eunice Wang, MD , Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML).
  • After one treatment cycle, 73% of patients experienced clinical responses, and 86% of patients responded to treatment after two cycles.
  • Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York.
  • Rebecca Vogt, Roswell Park Comprehensive Cancer Center, 716-548-0482, [email protected]
    Annie Deck-Miller, Roswell Park Comprehensive Cancer Center, 716-845-8593, [email protected]

Cellworks Personalized Therapy Biosimulation Study Identifies Novel Biomarkers Predictive of Response in AML Patients

Retrieved on: 
Tuesday, December 14, 2021

In the study, the Cellworks Biosimulation Platform and CBM was used to assess cytarabine (ARA-C) and anthracycline response and novel biomarker response criteria for the addition of etoposide (VP16) in AML.

Key Points: 
  • In the study, the Cellworks Biosimulation Platform and CBM was used to assess cytarabine (ARA-C) and anthracycline response and novel biomarker response criteria for the addition of etoposide (VP16) in AML.
  • The study found that Cellworks biosimulation identifies novel biomarkers that predict therapy response in AML patients, which offers the opportunity to tailor FDA-approved chemotherapy regimens to each patient to improve disease control and minimize toxicity.
  • From comprehensive genomic inputs, the Cellworks Biosimulation Platform identifies pathway based polygenic biomarkers that predict the efficacy of novel drug combinations and new drugs for AML patients, said Dr. Michael Castro, MD, Chief Medical Officer at Cellworks.
  • The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients.

Jacobson Pharma Announces FY2022 Interim Results

Retrieved on: 
Friday, November 26, 2021

The Board has resolved to declare an increased interim dividend by 50% to HK1.2 cents per share for the six months ended 30 September 2021 (FY2021 Interim: HK0.8 cent).

Key Points: 
  • The Board has resolved to declare an increased interim dividend by 50% to HK1.2 cents per share for the six months ended 30 September 2021 (FY2021 Interim: HK0.8 cent).
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated with the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2021 ACN Newswire .